Benchling is a cloud-based platform for biotechnology research and development. It has seen rapid growth and has cemented its position as a pioneer for bringing science and technology together to support the community in accelerating scientific discoveries.
Benchling wanted to break into the European market, following its success in the US. In 2021, it had a limited profile in the region and no media presence.
Taking a two-pronged approach, we run a high impact press office programme, using customer voices such as AstraZeneca, alongside investment stories and other strategic announcements, to demonstrate Benchling’s growth and its impact on the biotech industry. The second part of the programme uses ongoing thought leadership through interviews and opinion articles, to position the company as an innovator in cloud R&D.
We have secured coverage on Sky News and BBC.co.uk, and interviews with the Financial Times, Forbes and Bloomberg.
Thought leadership topics from both Benchling’s customers and its own senior leaders cover topics ranging from rare diseases, to the digital transformation of life sciences, to cyber security in scientific R&D, to the power of data to solve food scarcity. All of which is helping raise its profile as a key driver of innovation in the European Life Sciences market.